So why do new users, those who start statins after a cancer diagnosis, seem to show a more consistent survival benefit than those who were already on them?

Yeah.

That was one of the most striking and honestly counterintuitive findings, because one would expect that longer exposure means more benefit.

But what we saw when going through the published literature was the opposite, and the signal was strongest in women who started statins after their cancer diagnosis.

And there are a few possible explanations.

And here I think it's important to talk about both the biological and the methodological side.

First, biologically, there is a plausible story.

Um, what is it about the chemical structure of these fat-soluble statins that might allow them to enter cancer cells more easily than hydrophilic ones? And why does this distinction matter for oncologic outcomes?"